# A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

> **NCT07406347** · PHASE1 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 60 (estimated)

## Conditions studied

- Pneumonia, Bacterial

## Interventions

- **BIOLOGICAL:** Pn-MAPS30plus
- **COMBINATION_PRODUCT:** PCV20

## Key facts

- **NCT ID:** NCT07406347
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2028-04-03
- **Final completion:** 2028-04-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406347, "A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07406347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*